Skip to main content
SpringerLink
Log in

Gastrointestinal and intraabdominal infections

  • Chapter
  • First Online:
Fluoroquinolone Antibiotics

Part of the book series: Milestones in Drug Therapy ((MDT))

Abstract

The fluoroquinolones have excellent in vitro activity against a variety of gastrointestinal pathogens including enteropathogenic Escherichia coli, Salmonella spp., Shigella spp., Yersinia enterocolitica, Aeromonas hydrophila, Plesiomonas shigelloides, and Helicobacter pylori [1-4]. The newer fluoroquinolones (trovafloxacin, gatifloxacin, gemifloxacin) are also active against many obligate anaerobes [5, 6]. Coupled with favorable bioavailability after oral administration, and the ability to achieve high concentrations in the intestinal mucosa, hepatobiliary tree, and in feces, it is not surprising that this antibiotic class has been studied extensively for the treatment of gastrointestinal infections. This chapter will review the impact of fluoroquinolones on the fecal flora, and their major clinical applications in gastrointestinal and intraabdominal infections. Particular emphasis is directed to large randomized, double-blind and controlled clinical trials before and since 1995.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Karlowsky JA, Kelly LJ, Thomsberry C, Jones ME, Evangelista AT, Critchley IA, Sahm DF (2002) Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network. Int JAntimicrob Agents 19: 21–31

    CAS  Google Scholar 

  2. Goossens H, De Mol P, Coignau H, Levy J, Grados O, Ghysels G, Innocent H, Butzler JP (1985) Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR810 (a new cephalosporin), RU28965 (a new macrokide), and other agents against enteropathogens. Antimicrob Agents Chemother 27: 388–392

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Fernandez-Roblas R, Cabria F, Esteban J, Lopez JC, Gadea I, Soriano F (2000) In vitro activity of gemifloxacin (SB-265805) compared with 14 other antimicrobials against intestinal pathogens. J Antimicrob Chemother 46: 1023–1027

    CAS  PubMed  Google Scholar 

  4. Rhomberg PR, Biedenbach DJ, Jones RN (2001) Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp. Diagn Microbio! Infect Dis 40: 45–49

    CAS  Google Scholar 

  5. Ackermann G, Schaumann R, Pless B, Claros MC, Goldstein EJ, Rodloff AC (2000) Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria. Eur J Clin Microbiol Infect Dis 19: 228–232

    Google Scholar 

  6. Appelbaum PC (1999) Quinolone activity against anaerobes. Drugs 58 (Suppl 2): 60–64

    CAS  PubMed  Google Scholar 

  7. Korten V, Murray BE (1993) Impact of the fluoroquinolones on gastrointestinal flora. Drugs 45 (Suppl 3): 125–133

    PubMed  Google Scholar 

  8. Rohwedder RW, Bergan T, Thorsteinsson SB, Scholl H (1990) Transintestinal elimination of ciprofloxacin. Diagn Microbiol Infect Dis 13: 127–133

    CAS  PubMed  Google Scholar 

  9. Melnik G, Schwesinger WH, Teng R, Dogolo LC, Vincent J (1998) Hepatobiliary elimination of trovafloxacin and metabolites following single oral doses in healthy volunteers. Eur J Clin Microbio! Infect Dis 17: 424–426

    CAS  Google Scholar 

  10. Wise R (1999) A review of the clinical pharmacology of moxifloxacin, a new 8-methoxyquinolone, and its potential relation to therapeutic efficacy. Clin Drug Invest 17: 365–387

    CAS  Google Scholar 

  11. Dalvie DK, Khosla N, Vincent J (1997) Excretion and metabolism of trovafloxacin in humans. Drug Metab Dispos 25: 423–427

    CAS  PubMed  Google Scholar 

  12. Hooper DC (2000) New uses for new and old quinolones and the challenge of resistance. Clin Infect Dis 30: 243–254

    CAS  PubMed  Google Scholar 

  13. Edlund C, Nord CE (1999) Ecological effect of gatifloxacin on the normal human intestinal microflora. J Chemother 11: 50–53

    CAS  PubMed  Google Scholar 

  14. Schaumann R, Ackermann G, Pless B, Claros MC, Goldstein EJ, Rodloff AC (2000) In vitro activides of fourteen antimicrobial agents against obligately anaerobic bacteria. Int J Antimicrob Agents 16: 225–232

    CAS  PubMed  Google Scholar 

  15. Edlund C, Nord CE (1999) Effect of quinolones on intestinal ecology. Drugs 58 (Supp12): 65–70

    CAS  PubMed  Google Scholar 

  16. Edlund C, Lindqvist L, Nord CE (1988) Norfloxacin binds to human fecal material. Antimicrob Agents Chemother 32: 1869–1874

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Alonso R, Pelaez T, Gonzalez-Abad MJ, Alcala L, Munoz P, Rodriguez-Creixems M, Bouza E (2001) In vitro activity of new quinolones against Clostridium difficile. JAntimicrob Chemother 47: 195–197

    CAS  Google Scholar 

  18. Ozawa TT, Valadez T (2002) Clostridium difficile infection associated with levofloxacin treatment. Tenn Med 95: 113–115

    PubMed  Google Scholar 

  19. Yip C, Loeb M, Salama S, Moss L, Olde J (2001) Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea. Infect Control Hosp Epidemiol 22: 572–575

    CAS  PubMed  Google Scholar 

  20. McFarland LV, Bauwens JE, Melcher SA, Surawicz CM, Greenberg RN, Elmer GW (1995) Ciprofloxacin-associated Clostridium difficile disease. Lancet 346: 977–978

    CAS  PubMed  Google Scholar 

  21. Richard P, Delangle MH, Raffi F, Espaze E, Richet H (2001) Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant Gram-negative bacilli from gastrointestinal flora. Clin Infect Dis 32: 162–166

    CAS  PubMed  Google Scholar 

  22. DuPont HL, Ericsson CD (1993) Prevention and treatment of traveler’s diarrhea. New Engl J Med 328: 1821–1827

    CAS  PubMed  Google Scholar 

  23. Gortz G, Boese-Landgraf J, Hopfenmuller W, Rodloff A, Kotwas J (1990) Ciprofloxacin as single-dose antibiotic prophylaxis in colorectal surgery: results of a randomized, double-blind trial. Diag Micro Infect Dis 13: 181–185

    CAS  Google Scholar 

  24. Brismar B, Edlund C, Malmborg AS, Nord CE (1990) ciprofloxacin concentrations and impact of the colon microflora in patients undergoing colorectal surgery. Antimicrob Agents Chemother 34: 481–483

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Giuliano M, Pantosti A, Gentile G, Venditti M, Arcese W, Martino P (1989) Effects on oral and intestinal microfloras of norfloxacin and pefloxacin for selective decontamination in bone marrow transplant patients. Antimicmb Agents Chemother 33: 1709–1713

    CAS  Google Scholar 

  26. Rozenberg-Arska M, Dekker AW, Verhoef J (1985) Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora. J Infect Dis 152: 104–107

    CAS  PubMed  Google Scholar 

  27. Ericsson CD, DuPont HL (1993) Travelers’ diarrhea: approaches to prevention and treatment. Clin Infect Dis 16: 616–626

    CAS  PubMed  Google Scholar 

  28. Adachi JA, Ostrosky-Zeichner L, DuPont HL, Ericsson CD (2000) Empirical antimicrobial therapy for traveler’s diarrhea. Clin Infect Dis 31: 1079–1083

    CAS  PubMed  Google Scholar 

  29. Taylor DN, Sanchez JL, Candler W, Thornton S, McQueen C, Echeverria P (1991) Treatment of travelers’ diarrhea: ciprofloxacin plus loperamide compared with ciprofloxacin alone. A placebo-controlled, randomized trial. Ann Intern Med 114: 731–734

    CAS  PubMed  Google Scholar 

  30. Petruccelli BP, Murphy GS, Scnchez JL, Walz S, DeFraites R, Gelnett J, Laberberger RL, Echeverria P, Taylor DN (1992) Treatment of traveler’s diarrhea with ciprofloxacin and loperamide. J Infect Dis 165: 557–560

    CAS  PubMed  Google Scholar 

  31. Ericsson CD, DuPont HL, Mathewson II (1997) Single dose ofloxacin plus loperamide compared with single dose or three days of ofloxacin in the treatment of traveler’s diarrhea. J Travel Med 4: 3–7

    CAS  PubMed  Google Scholar 

  32. Rademaker CMA, Hoepelman IM, Wolfhagen MJHM et al (1989) Results of a double-blind placebo-controlled study using ciprofloxacin for prevention of traveler’s diarrhea. Eur J Clin Microbiol 8: 690–694

    CAS  Google Scholar 

  33. Wistrom JNSR, Burman LG, Lundholm R, Jellheden B et al (1987) Norfloxacin versus placebo for prophylaxis against travellers’ diarrhea. JAntimicrob Chemother 20: 563–574

    CAS  Google Scholar 

  34. Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV, Hennessy T, Griffin PM, DuPont H, Sack RB et al (2001) Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 32: 331–351

    CAS  PubMed  Google Scholar 

  35. Goodman IJ, Trenholme GM, Kaplan RL et al (1990) Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults. Arch Intern Med 150: 546

    Google Scholar 

  36. Butler T, Lolekha S, Rasidi C, Kadio A, Del Rosal PL, Iskandar H, Rubinstein E, Pastore G (1993) Treatment of acute bacterial diarrhea: a multicenter international trial comparing placebo with fleroxacin given as a single dose or once daily for 3 days. Am JMed 94 (suppl 3A): 187S–194S

    Google Scholar 

  37. Noguerado A, Garcia-Polo I, Isasia T, Jimenez ML, Bermudez P, Pita J, Gabriel R (1995) Early single dose therapy with ofloxacin for empirical treatment of acute gastroenteritis: a randomized placebo-controlled double-blind clinical trial. JAntimicrob Chemother 36: 665–672

    CAS  Google Scholar 

  38. Halstensen A, Voltersvik P, Gossius GDA, Peterson LE, Rolstad T, Solberg CO (1995) Double-blind comparison of ofloxacin for 3 days and placebo in acute bacterial enteritis. Drugs 49: 52–54

    Google Scholar 

  39. Akalin HE (1995) Role of quinolones in the treatment of diarrhoeal diseases. Drugs 49: 1–4

    Google Scholar 

  40. Neill MA, Opal SM, Heelan J et al (1991) Failure of ciprofloxacin to eradicate convalescent faecal excretion after acute salmonellosis: experience during an outbreak in health care workers. Ann Intern Med 114: 195–199

    CAS  PubMed  Google Scholar 

  41. Davis R, Markham A, Balfour JA (1996) Ciprofloxacin: an updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs 51: 1019–1074

    CAS  PubMed  Google Scholar 

  42. Limson BM (1995) Short course quinolone therapy of typhoid fever in developing countries. Drugs 49: 27–29

    Google Scholar 

  43. Smith MD, Duong NM, Hoa NT, Wain J, Ha HD, Diep TS, Day NP, Hien TT, White NJ (1994) Comparison of ofloxacin and ceftriaxone for short-course treatment of enteric fever. Antimicrob Agents Chemother 38: 1716–1720

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Ferreccio C, Morris JG Jr, Valdivieso C, Prenzel I, Sotomayor V, Drusano GL, Levine MM (1988) Efficacy of ciprofloxacin in the treatment of chronic typhoid carriers. J Infect Dis 157: 1235–1239

    CAS  PubMed  Google Scholar 

  45. Zavala T, I, Quiroz C, Gutierrez MA, Arias J, Renteria M (1991) Fluoroquinolones in the treatment of typhoid fever and the carrier state. Eur J Clin Microbiol Infect Dis 10: 334–341

    Google Scholar 

  46. Gotuzzo E, Guerra JG, Benavente L, Palomino JC, Carrillo C, Lopera J, Delgado F, Nalin DR, Sabbaj J (1988) Use of norfloxacin to treat chronic typhoid carriers. J Infect Dis 157: 1221–1225

    CAS  PubMed  Google Scholar 

  47. Murphy GS, Bodhidatta L, Echeverria P, Tansuphaswadikul S, Hoge CW, Imlarp S, Tamura K (1993) Ciprofloxacin and loperamide in the treatment of bacillary dysentery. Ann Intern Med 118: 582–586

    CAS  PubMed  Google Scholar 

  48. Bennish ML, Salam MA, Khan WA, Khan AM (1992) Treatment of shigellosis: III. Comparison of one-or two-dose ciprofloxacin with standard 5-day therapy. A randomized, blinded trial. Ann Intern Med 117: 727–734

    CAS  PubMed  Google Scholar 

  49. Bennish ML, Salam MA, Hossain MA, Myaux J, Khan EH, Chakraborty J, Henry F, Ronsmans C (1992) Antimicrobial resistance of Shigella isolates in Bangladesh, 1983–1990: increasing frequency of strains multiply resistant to ampicillin, trimethoprim-sulfamethoxazole, and nalidixic acid. Clin Infect Dis 14: 1055–1060

    CAS  PubMed  Google Scholar 

  50. Khan WA, Bennish ML, Seas C, Khan EH, Ronan A, Dhar U, Busch W, Salam MA (1996) Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae 01 or 0139. Lancet 348: 296–300

    CAS  PubMed  Google Scholar 

  51. Mattila L, Peltola H, Siitonen A, Kyronseppa H, Simula I, Kataja M (1993) Short-term treatment of traveler’s diarrhea with norfloxacin: a double-blind, placebo-controlled study during two seasons. Clin Infect Dis 17: 779–782

    CAS  PubMed  Google Scholar 

  52. Dryden MS, Gabb RJ, Wright SK (1996) Empirical treatment of severe acute community-acquired gastroenteritis with ciprofloxacin. Clin Infect Dis 22: 1019–1025

    CAS  PubMed  Google Scholar 

  53. Adler-Mosca H, Luthy-Hottenstein J, Martinetti LG, Bumens A, Altwegg M (1991) Development of resistance to quinolones in five patients with campylobacteriosis treated with norfloxacin or ciprofloxacin. Eur J Clin Microbiol Infect Dis 10: 953–957

    CAS  PubMed  Google Scholar 

  54. Obana M, Matsuoka Y, Irimajiri S, Tonooka H (1992) [Clinical studies on the treatment of Campylobacter enteritis — emergence of quinolone-resistant Campylobacter jejuni after treatment with new quinolones]. Kansenshogaku Zasshi 66: 923–929

    CAS  PubMed  Google Scholar 

  55. Wretlind B, Stromberg A, Ostlund L, Sjogren E, Kaijser B (1992) Rapid emergence of quinolone resistance in Campylobacter jejuni in patients treated with norfloxacin. Scand J Infect Dis 24: 685–686

    CAS  PubMed  Google Scholar 

  56. Engberg J, Aarestrup FM, Taylor DE, Gerner-Smidt P, Nachamkin I (2001) Quinolone and macrolide resistance in Campylobacter jejuni and C. colt: resistance mechanisms and trends in human isolates. Emerg Infect Dis 7: 24–34

    CAS  PubMed  PubMed Central  Google Scholar 

  57. DuPont HL (1995) Antimicrobial-resistant Campylobacter species — a new threat to travelers to Thailand. Clin Infect Dis 21: 542–543

    CAS  PubMed  Google Scholar 

  58. Sjogren E, Lindblom GB, Kaijser B (1997) Norfloxacin resistance in Campylobacter jejuni and Campylobacter colt isolates from Swedish patients. JAntimicrob Chemother 40: 257–261

    CAS  Google Scholar 

  59. Smith KE, Besser JM, Hedberg CW, Leano FT, Bender JB, Wicklund JH, Johnson BP, Moore KA, Osterholm MT, The Investigation Team (1999) Quinolone-Resistant Campylobacter jejuni Infections in Minnesota, 1992–1998. N Engl J Med 340: 1525–1532

    CAS  PubMed  Google Scholar 

  60. Kuschner RA, Trofa AF, Thomas RJ, Hoge CW, Pitarangsi C, Amato S, Olafson RP, Echeverria P, Sadoff JC, Taylor DN (1995) Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin Infect Dis 21: 536–541

    CAS  PubMed  Google Scholar 

  61. Rohwedder R, Bonadeo F, Benati M, Ojea QG, Schiecker H, Vaccaro C (1993) Single-dose oral ciprofloxacin plus parenteral metronidazole for perioperative antibiotic prophylaxis in colorectal surgery. Chemotherapy 39: 218–224

    CAS  PubMed  Google Scholar 

  62. Milsom JW, Smith DL, Corman ML, Howerton RA, Yellin AE, Luke DR, Trovafloxacdin Surgical Group (1998) Double-blind comparison of single-dose alatroflaxacin and cefotetan as prophylaxis of infection following elective colorectal surgery. Am J Surg 176 (Suppl 6A): 46S–52S

    Google Scholar 

  63. Cruciani M, Rampazzo R, Malena M, Lazzarini L, Todeschini G, Messori A, Concia E (1996) Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 23: 795–805

    CAS  PubMed  Google Scholar 

  64. GIMEMAInfection Program (1991) Prevention of bacterial infection in neutropenic patients with hematologic malignancies. A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. The GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto. Ann Intern Med 115: 7–12

    Google Scholar 

  65. D’Antonio D, Piccolomini R, Iacone A, Fioritoni G, Parruti G, Betti S, Quaglietta AM, Accorsi P, Dell’Isola M, Favalli C (1994) Comparison of ciprofloxacin, ofloxacin and pefloxacin for the prevention of the bacterial infection in neutropenic patients with haematological malignancies. J Antimicrob Chemother 33: 837–844

    PubMed  Google Scholar 

  66. Carratala J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F (1995) Emergence of quinoloneresistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 20: 557–560

    CAS  PubMed  Google Scholar 

  67. Oethinger M, Jellen-Ritter AS, Conrad S, Marre R, Kern WV (1998) Colonization and infection with fluoroquinolone-resistant Escherichia coli among cancer patients: clonal analysis. Infection 26: 379–384

    CAS  PubMed  Google Scholar 

  68. Navasa M, Folio A, Llovet JM, Clemente G, Vargas V, Rimola A, Marco F, Guarner C, Forne M, Planas R et al (1996) Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology 111: 1011–1017

    CAS  PubMed  Google Scholar 

  69. Hsieh WJ, Lin HC, Hwang SJ, Hou MC, Lee FY, Chang FY, Lee SD (1998) The effect of ciprofloxacin in the prevention of bacterial infection in patients with cirrhosis after upper gastrointestinal bleeding. Am J Gastroenterol 93: 962–966

    CAS  PubMed  Google Scholar 

  70. Gines P, Rimola A, Planas R et al (1990) Norfloxacin prevents spontaneous bacterial peritonitis recurrence in dirrhosis: resultws of a double-blind, placebo-controlled trial. Hepatology 12: 716–724

    CAS  PubMed  Google Scholar 

  71. Dupeyron C, Mangeney N, Sedrati Let al (1994) Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. Antimicrob Agents Chemother 38: 340–344

    CAS  PubMed  PubMed Central  Google Scholar 

  72. Perez-Fontan M, Rosales M, Fernandez F et al (1993) Treatment of CAPD peritonitis with ciprofloxacin — long-term results. Nefrologia 13: 149–154

    Google Scholar 

  73. Fnedlan JS, Iveson TJ, Frise AP et al (1990) A comparison between intraperitoneal ciprofloxacin and intraperitoneal vancomycin and gentamicin in the treatment of peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD). JAntimicrob Chemother 26 (Suppl F): 77–81

    Google Scholar 

  74. Cheng IK, Chan CY, Wong WT et al (1993) A randomized prospective comparison of oral versus intraperitoneal ciprofloxacin as the primary treatment of peritonitis complicating continuous ambulatory peritoneal dialysis. Petit Dial Int 13 (Suppl 2): S351–5354

    Google Scholar 

  75. Chan MK, Chau PY, Chan WWN (1988) Oral treatment of peritonitis in CAPD patients with two dosage regimens of ofloxacin. J Antimicrob Chemother 22: 371–375

    CAS  PubMed  Google Scholar 

  76. Dryden MS, Talsania H, McCann M et al (1992) The epidemiology of ciprofloxacin resistance in coagulase-negative staphylococci in CAPD patients. Epdemiol Inf 109: 97–112

    CAS  Google Scholar 

  77. Edmiston CE Jr, Suarez EC, Walker AP, Demeure MP, Frantzides CT, Schulte WJ, Wilson SD (1996) Penetration of ciprofloxacin and fleroxacin into biliary tract. Antimicrob Agents Chemother 40: 787–791

    CAS  PubMed  PubMed Central  Google Scholar 

  78. Hayton WL, Vlahov V, Bacracheva N, Viachki I, Portmann R, Muirhead G, Stoeckel K, Weidekamm E (1990) Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients. Antimicrob Agents Chemother 34: 2375–2380

    CAS  PubMed  PubMed Central  Google Scholar 

  79. van den Hazel SJ, de Vries XH, Speelman P, Dankert J, Tytgat GN, Huibregtse K, van Leeuwen DJ (1996) Biliary excretion of ciprofloxacin and piperacillin in the obstructed biliary tract. Antimicrob Agents Chemother 40: 2658–2660

    PubMed  PubMed Central  Google Scholar 

  80. Westphal JF, Brogard JM (1999) Biliary tract infections: a guide to drug treatment. Drugs 57: 81–91

    CAS  PubMed  Google Scholar 

  81. Karachalios GN, Zografos G, Patrikakos V (1993) Biliary tract infections treated with ciprofloxacin. Infection 21: 362–364

    Google Scholar 

  82. Sung JJ, Lyon DJ, Suen R, Chung SC, Co AL, Cheng AF, Leung JW, Li AK (1995) Intravenous ciprofloxacin as treatment for patients with acute suppurative cholangitis: a randomized, controlled clinical trial. J Antimicrob Chemother 35: 855–864

    CAS  PubMed  Google Scholar 

  83. Byl B, Deviere J, Struelens MJ, Roucloux I, De Coninck A, Thys JP, Cremer M (1995) Antibiotic prophylaxis for infectious complications after therapeutic endoscopie retrograde cholangiopancreatography: a randomized, double-blind, placebo-controlled study. Clin Infect Dis 20: 1236–1240

    CAS  PubMed  Google Scholar 

  84. Vincent J, Teng R, Dalvie DK, Friedman HL (1998) Pharmacokinetics and metabolism of single oral doses of trovafloxacin. Am J Surg 176: 8S–13S

    CAS  PubMed  Google Scholar 

  85. Harris A, Chan AC, Torres-Viera C, Hammett R, Carr-Locke D (1999) Meta-analysis of antibiotic prophylaxis in endoscopie retrograde cholangiopancreatography (ERCP). Endoscopy 31: 718–724

    CAS  PubMed  Google Scholar 

  86. Subhani JM, Kibbler C, Dooley JS (1999) Review article: antibiotic prophylaxis for endoscopie retrograde cholangiopancreatography (ERCP). Aliment Pharmacol Ther 13: 103–116

    CAS  PubMed  Google Scholar 

  87. Rey JR, Axon A, Budzynska A, Kruse A, Nowak A (1998) Guidelines of the European Society of Gastrointestinal Endoscopy (E.S.G.E.) antibiotic prophylaxis for gastrointestinal endoscopy. European Society of Gastrointestinal Endoscopy. Endoscopy 30: 318–324

    CAS  PubMed  Google Scholar 

  88. Deshpande LM, Diekema DJ, Jones RN (1999) Comparative activity of clinafloxacin and nine other compounds tested against 2000 contemporary clinical isolates from patients in United States hospitals. Diagnostic Microbiology and Infectious Disease 35: 81–88

    CAS  PubMed  Google Scholar 

  89. Schaumann R, Ackermann G, Pless B, Claros MC, Rodloff AC (1999) In vitro activities of gatifloxacin, two other quinolones, and five nonquinolone antimicrobials against obligately anaerobic bacteria. Antimicrob Agents Chemother 43: 2783–2786

    CAS  PubMed  PubMed Central  Google Scholar 

  90. Yoshioka K, Youngs DJ, Keighley MRB (1991) A randomized prospective controlled study of ciprofloxacin with metronidazole versus amoxicillin/clavulanic acid with metronidazole in the treatment of intra-abdominal infection. Infection 19: 25–29

    CAS  PubMed  Google Scholar 

  91. Hoogkamp-Korstanje JAA (1995) Ciprofloxacin versus cefotaxime regimens for the treatment of intra-abdominal infections. Infection 23: 278–282

    CAS  PubMed  Google Scholar 

  92. Solomkin JS, Reinhart HH, Dellinger EP, Bohnen JM, Rotstein OD, Vogel SB, Simms HH, Hill CS, Bjornson HS, Haverstock DC et al (1996) Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intraabdominal infections. The Intra-Abdominal Infection Study Group. Ann Surg 223: 303–315

    CAS  PubMed  PubMed Central  Google Scholar 

  93. Walters DJ, Solomkin JS, Paladino JA (1999) Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastatin in the treatment of intra-abdominal infections. Pharmacoeconomics 16: 551–561

    CAS  PubMed  Google Scholar 

  94. Madrid AM, Hurtado C, Venegas M, Cumsille F, Defilippi C (2001) Long-Term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function. Am J Gastroenterol 96: 1251–1255

    CAS  PubMed  Google Scholar 

  95. Donahue PE, Smith DL, Yellin AE, Mintz SJ, Bur F, Luke DR, Trovafloxacin Surgical Group (1998) Trovafloxacin in the treatment of intra-abdominal infections: results of a double-blind, multicenter comparison with imipenem/cilastatin. Am J Surg 176 (Suppl 6A): 53S–61S

    Google Scholar 

  96. Roy S, Koltun W, Chatwani A, Martens MG, Dittrich R, Luke DR (1998) Treatment of acute gyne-cologic infections with trovafloxacin. Trovafloxacin Surgical Group. Am J Surg 176: 67S–73S

    CAS  PubMed  Google Scholar 

  97. Solomkin JS, Wilson SE, Christou NV, Rotstein OD, Dellinger EP, Bennion RS, Pak R, Tack K (2001) Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections. Ann Surg 233: 79–87

    CAS  PubMed  PubMed Central  Google Scholar 

  98. Minehart HW, Chalker AF (2001) In vitro activity of gemifloxacin against Helicobacter pylori. J Antimicrob Chemother 47: 360–361

    CAS  PubMed  Google Scholar 

  99. Glupczynski Y, Labbe M, Burette A, Delmee M, Avesani V, Bruck C (1987) Treatment failure of ofloxacin in Campylobacter pylori infection. Lancet 1: 1096

    CAS  PubMed  Google Scholar 

  100. Mertens JC, Dekker W, Ligtvoet EE, Blok P (1989) Treatment failure of norfloxacin against Campylobacter pylori and chronic gastritis in patients with nonulcerative dyspepsia. Antimicrob Agents Chemother 33: 256–257

    CAS  PubMed  PubMed Central  Google Scholar 

  101. Stone JW, Wise R, Donovan IA, Gearty J (1988) Failure of ciprofloxacin to eradicate Campylobacter pylori from the stomach. JAntimicrob Chemother 22: 92–93

    CAS  Google Scholar 

  102. Andriole VT (1993) The future of the quinolones. Drugs 45 (syook 3): 1–7

    CAS  PubMed  Google Scholar 

  103. Dresner D, Coyle W, Nemec R, Peterson R, Duntemann T, Lawson JM (1996) Efficacy of ciprofloxacin in the eradication of Helicobacter pylori. South Med J 89: 775–778

    CAS  PubMed  Google Scholar 

  104. Gupta VK, Dhar A, Srinivasan S, Rattan A, Sharma MP (1997) Eradication of H. pylori in a developing country: comparison of lansoprazole versus omeprazole with norfloxacin, in a dual-therapy study. Am J Gastroenterol 92: 1140–1142

    CAS  PubMed  Google Scholar 

  105. Cammarota G, Cianci R, Cannizzaro O, Cuoco L, Pirozzi G, Gasbarrini A, Armuzzi A, Zocco MA, Santarelli L, Arancio F et al (2000) Efficacy of two one-week rabeprazole/levofloxacinbased triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 14: 1339–1343

    CAS  PubMed  Google Scholar 

  106. Sanchez JE, Saenz NG, Rincon MR, Martin IT, Sanchez EG, Martinez MJ (2000) Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones. J Antimicrob Chemother 46: 283–285

    CAS  PubMed  Google Scholar 

  107. Carbone M, Fera MT, Cecchetti V, Tabarrini O, Losi E, Cusumano V, Teti G (1997) In vitro activities of new quinolones against Helicobacter pylori. Antimicrob Agents Chemother 41: 2790–2792

    CAS  PubMed  PubMed Central  Google Scholar 

  108. Krueger WA, Ruckdeschel G, Unertl K (1997) Influence of intravenously administered ciprofloxacin on aerobic intestinal microflora and fecal drug levels when administered simultaneously with sucralfate. Antimicrob Agents Chemother 41: 1725–1730

    CAS  PubMed  PubMed Central  Google Scholar 

  109. Krueger WA, Ruckdeschel G, Unertl K (1999) Elimination of fecal Enterobacteriaceae by intravenous ciprofloxacin is not inhibited by concomitant sucralfate — a microbiological and pharmacokinetic study in patients. Infection 27: 335–340

    CAS  PubMed  Google Scholar 

  110. Cofsky RD, duBouchet L, Landesman SH (1984) Recovery of norfloxacin in feces after administration of a single oral dose to human volunteers. Antimicrob Agents Chemother 26: 110–111

    CAS  PubMed  PubMed Central  Google Scholar 

  111. Pecquet S, Andremont A, Tancrede C (1987) Effect of oral ofloxacin on fecal bacteria in human volunteers. Antimicrob Agents Chemother 31: 124–125

    CAS  PubMed  PubMed Central  Google Scholar 

  112. Edlund C, Sjostedt S, Nord CE (1997) Comparative effects of levofloxacin and ofloxacin on the normal oral and intestinal microflora. Scand J Infect Dis 29: 383–386

    CAS  PubMed  Google Scholar 

  113. Midtvedt T (1987) Influence of ofloxacin on the faecal flora. Drugs 34 (Suppl 1): 154–158

    CAS  PubMed  Google Scholar 

  114. Janin N, Meugnier H, Desnottes JF, Woehrle R, Fleurette J (1987) Recovery of pefloxacin in saliva and feces and its action on oral and fecal floras of healthy volunteers. Antimicrob Agents Chemother 31: 1665–1668

    CAS  PubMed  PubMed Central  Google Scholar 

  115. Nakashima M, Kanamaru M, Uematsu T, Takiguchi A, Mizuno A, Itaya T, Kawahara F, Ooie T, Saito S, Uchida H et al (1988) Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers. JAntimicrob Chemother 22 (Suppl D): 133–144

    CAS  Google Scholar 

  116. Garcia-Calvo G, Molleja A, Gimenez MJ, Parra A, Nieto E, Ponte C, Aguilar L, Soriano F (2001) Effects of single oral doses of gemifloxacin (320 milligrams) versus trovafloxacin (200 milligrams) on fecal flora in healthy volunteers. Antimicrob Agents Chemother 45: 608–611

    CAS  PubMed  PubMed Central  Google Scholar 

  117. Stass H, Kubitza D (1999) Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. JAntimicrob Chemother 43 (Suppl B): 83–90

    Google Scholar 

  118. Vries-Hospers HG, Welling GW, van der WD (1987) Influence of quinolones on throat-and faecal flora of healthy volunteers. Pharm Weekbl Sci 9 (Suppl): S41–S44

    Google Scholar 

  119. Bergan T, Delin C, Johansen S, Kolstad IM, Nord CE, Thorsteinsson SB (1986) Pharmacokinetics of ciprofloxacin and effect of repeated dosage on salivary and fecal microflora. Antimicrob Agents Chemother 29: 298–302

    CAS  PubMed  PubMed Central  Google Scholar 

  120. Brumfitt W, Franklin I, Grady D, Hamilton-Miller JMT, Iliffe A (1984) Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human vol-unteers. Antimicrob Agents Chemother 26: 757–761

    CAS  PubMed  PubMed Central  Google Scholar 

  121. Shah PM, Enzensberger R, Glogau O, Knothe H (1987) Influence of oral ciprofloxacin or ofloxacin on fecal flora of healthy volunteers. Am J Med 82 (Suppl 4A): 333–335

    CAS  Google Scholar 

  122. Shah PM, Sammann A, Schafer V, Seczendi M, Knothe H (1988) Fleroxacin: safety, tolerance and effect on the faecal flora of healthy volunteers. J Antimicrob Chemother 22 (Suppl D): 209–213

    CAS  PubMed  Google Scholar 

  123. van Nispen CH, Hoepelman AI, Rozenberg-Arska M, Verhoef J, Purkins L, Willavize SA (1998) A double-blind, placebo-controlled, parallel group study of oral trovafloxacin on bowel microflora in healthy male volunteers. Am J Surg 176: 27S–31S

    PubMed  Google Scholar 

  124. Edlund C, Beyer G, Hiemer-Bau M, Ziege S, Lode H, Nord CE (2000) Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora. Scand J Infect Dis 32: 81–85

    CAS  PubMed  Google Scholar 

  125. Barker PJ, Sheehan R, Teillol-Foo M, Palmgren AC, Nord CE (2001) Impact of gemifloxacin on the normal human intestinal microflora. J Chemother 13: 47–51

    CAS  PubMed  Google Scholar 

  126. DuPont H, Corrado ML, Subbaj J (1987) Use of norfloxacin in the treatment of acute diarrheal disease. Am J Med 82 (Suppl 6B): 79–83

    CAS  PubMed  Google Scholar 

  127. DuPont H, Ericsson CD, Mathewson JJ et al (1992) Five versus three days of ofloxacin therapy for traveller’s diarrhoea: a placebo-controlled study. Antimicrob Agents Chemother 36: 87–91

    CAS  PubMed  PubMed Central  Google Scholar 

  128. Salam I, Katelaris P, Leigh-Smith s Farthing MJG (1994) Randomised trial of single-dose ciprofloxacin for travellers’ diarrhea. Lancet 344: 1537–1539

    CAS  PubMed  Google Scholar 

  129. Wistrom J, Jertborn M, Ekwall E, Norlin K, Soderquist B, Stromberg A, Lundholm R, Hogevik H, Lagergren L, Englund G et al (1992) Empiric treatment of acute diarrheal disease with norfloxacin. A randomized, placebo-controlled study. Swedish Study Group. Ann Intern Med 117: 202–208

    CAS  PubMed  Google Scholar 

  130. Sanchez C, Garcia-Restoy E, Garau J, Bella F, Freixas N, Simo M, Lite J, Sanchez P, Espejo E, Cobo E et al (1993) Ciprofloxacin and trimethoprim-sulfamethoxazole versus placebo in acute uncomplicated Salmonella enteritis: a double-blind trial. J Infect Dis 168: 1304–1307

    CAS  PubMed  Google Scholar 

  131. Limson BM, Littaua RT (1989) Comparative study of ciprofloxacin versus co-trimoxazole in the treatment of Salmonella enteric fever. Infection 17: 105–106

    CAS  PubMed  Google Scholar 

  132. Unal S, Hayran M, Tuncer S, Gur D, Uzun O, Akova M, Akalin HE (1996) Treatment of enteric fever with pefloxacin for 7 days versus 5 days: a randomized clinical trial. Antimicrob Agents Chemother 40: 2898–2900

    CAS  PubMed  PubMed Central  Google Scholar 

  133. Tran TH, Bethell DB, Nguyen TT, Wain J, To SD, Le TP, Bui MC, Nguyen MD, Pham TT, Walsh AL et al (1995) Short course of ofloxacin for treatment of multidrug-resistant typhoid. Clin Infect Dis 20: 917–923

    CAS  PubMed  Google Scholar 

  134. Uwaydah AK, al Soub H, Matar I (1992) Randomized prospective study comparing two dosage regimens of ciprofloxacin for the treatment of typhoid fever. J Antimicrob Chemother 30: 707–711

    CAS  PubMed  Google Scholar 

  135. Bennish ML, Salam MA, Haider R, Barza M (1990) Therapy for shigellosis. II. Randomized, double-blind comparison of ciprofloxacin and ampicillin. J Infect Dis 162: 711–716

    CAS  PubMed  Google Scholar 

  136. Salam MA, Bennish ML (1988) Therapy for shigellosis. I. Randomized, double-blind trial of nalidixic acid in childhood shigellosis. J Pediatr 113: 901–907

    CAS  PubMed  Google Scholar 

  137. Khan WA, Seas C, Dhar U, Salam MA, Bennish ML (1997) Treatment of shigellosis: V. Comparison of azithromycin and ciprofloxacin. A double-blind, randomized, controlled trial. Ann Intern Med 126: 697–703

    CAS  PubMed  Google Scholar 

  138. Gotuzzo E, Obergelman RA, Maguina C, Berry SJ, Yi a Guzman M, Ruiz R, Leon-Barua R, Sack RB (1989) Comparison of single-dose treatment with norfloxacin and standard 5-day treatment with trimethoprim-sulfamethoxazole for acute shigellosis in adults. Antimicrob Agents Chemother 33: 1101–1104

    CAS  PubMed  PubMed Central  Google Scholar 

  139. Gotuzzo E, Seas C, Echevarria J, Carrillo C, Mostorino R, Ruiz R (1995) Ciprofloxacin for the treatment of cholera: a randomized, double-blind, controlled clinical trial of a single daily dose in Peruvian adults. Clin Infect Dis 20: 1485–1490

    CAS  PubMed  Google Scholar 

  140. Khan WA, Begum M, Salam MA, Bardhan PK, Islam MR, Mahalanabis D (1995) Comparative trial of five antimicrobial compounds in the treatment of cholera in adults. Trans R Soc Trop Med Hyg 89: 103–106

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Department of Medicine, University of British Columbia and Vancouver Hospital Health Sciences Centre, Vancouver, B.C, V5Z 3J5, Canada

    Anthony W. Chow

Authors
  1. Anthony W. Chow
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Faculty of Medicine, The University of Manitoba, 409 Tacho Avenue, Winnipeg, Manitoba, R2H 2A6, Canada

    Allan R. Ronald

  2. Microbiology Laboratory, Mt. Sinai Hospital, 600 University Avenue, Toronto, Ontario, M5G 1X5, Canada

    Donald E. Low

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Basel AG

About this chapter

Cite this chapter

Chow, A.W. (2003). Gastrointestinal and intraabdominal infections. In: Ronald, A.R., Low, D.E. (eds) Fluoroquinolone Antibiotics. Milestones in Drug Therapy. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8103-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8103-6_8

  • Published:

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9437-1

  • Online ISBN: 978-3-0348-8103-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation